Disposition and blood brain barrier of CPU- 86017 (p- Chlorobenzyltetrahydroberberine) after iv and icv in mice

Journal of China Pharmaceutical University

Volumn 33, Issue 3, 2002, Pages 226-230

  Ciamala, Cibangu D ^a   Lin, Sheng ^a   Liu, Wen Tao ^a   Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Brain; CPU 86017; HPLC; Mouse; Pharmacokinetics; Toxicity

Indexed keywords

4 CHLOROBENZYLTETRAHYDROBERBERINE; ANTIARRHYTHMIC AGENT; CPU 86017; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG PENETRATION; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LD 50; MORTALITY; MOUSE; NONHUMAN; SEDATION;

EID: 21844464818     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Campbell RWF. Mortality in the evaluation of cardiovascular drugs. In: clinical measurement. In Drug Evaluation[M], Wolfe Publishing Ltd, England 1991. 5-11.
2. Packer, M. Sudden unexpected death in patients with congestive heart failure: a secondfrontier[J]. Circulation, 1985; 72: 681-85.
3. Dai DZ. The antiarrhythmic activity of protoberberines in relation to blockade of ion channels[J]. Ion Channel Modulators, 1997; 2 (10): 383-90.
4. Dai DZ, Yu F, Li HT, Tang YQ, An LF, Huang WL, et al. Blockade on sodium, potassium and calcium channels by a new anti- arrhythmic agent CPU-86017[J], Drug Dev Res, 1996, 39:138-146.
5. Dai DZ, An LF, Wang YQ, Huang Q, Zhang H, Dai D, et al. CPU-86017 suppression of arrhythmias induced by ischemia/ reperfusion, ouabain, aconitine, and elevation of ventricular fibrillatory threshold[J]. Drug Dev Res, 1996, 39:184-190.
6. Banks WA, Jaspan JB, Kastin AJ. Selective physiological transport of insulin across the blood-brain barrier by species-specific radioimmunoassay[J]. Peptides, 1997, 18: 1257-1262.
7. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion[J]. J Membr Biol, 1998, 165:201-211.
8. Tanabe S, Shimohigashi Y, Nakayama Y, et al. In vivo and in vitro evidence of blood- brain barrier transport of a novel cationic arginine- vasopressin fragment 4-9 analog[J]. J Pharmacol Exp Ther, 1999, 290:561-568.
9. ManessL M, Kastin AJ, Farrell CL, Banks WA. Fate of leptin after intracerebroventricular injection into the mouse brain[J]. Endrocrinology, 1998, 139(11): 4556-4562.
10. Monisha Sharma, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in brain and cognitive impairment[J]. Life Sciences, 2001, 68:1021-1029.
11. Takeda A, Suzuki M, Okada S, Oku N. 65Zn localization in rat brain after intracerebroventricular injection of 65Zn- histidine [J]. Brain Res, 2000 Apr 28; 863(1-2): 241-244.
12. 14C] DA-5018 to blood-brain barrier corrected with HPLC method [J]. Arch Pharmacol Res, 1999, 22(2): 165-172.
13. Owens HM, Destache CJ, Dash AK. Simple liquid chromatographic method for the analysis of the blood brain barrier permeability characteristics of ceftriaxone in an experimental rabbit meningitis model[J]. J Chromatogr B Biomed Sci Appl, 1999, 728(1) 97-105.
14. Li GM, Wang JP, Dai DZ, et al. Determination of 86017 concentrations in rat plasma by HPLC[J]. J Chin Pharm Uni, 1995, 29 (2): 97-99.
15. Robinson MM, McLennan GP, Thunhorst RL, Johnson AK. Interactions of the systemic and brain renin-angiotensin systems in the control of drinking and the central mediation of pressor responses[J]. Brain Res, 1999 Sep 18; 842(1): 55-61.